

Do-Youn Oh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7977536/publications.pdf>

Version: 2024-02-01

241
papers

14,264
citations

66250

44
h-index

29333

108
g-index

244
all docs

244
docs citations

244
times ranked

16215
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, 111-121. | 1.4 | 7 |
| 2 | Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 541-553. | 1.3 | 4 |
| 3 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217. | 2.7 | 9 |
| 4 | The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. <i>Molecular Oncology</i> , 2022, 16, 2355-2366. | 2.1 | 3 |
| 5 | Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). <i>Gastric Cancer</i> , 2022, 25, 609-618. | 2.7 | 3 |
| 6 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 234-247. | 5.1 | 268 |
| 7 | INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS366-TPS366. | 0.8 | 2 |
| 8 | A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 378-378. | 0.8 | 146 |
| 9 | Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS621-TPS621. | 0.8 | 0 |
| 10 | Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS639-TPS639. | 0.8 | 0 |
| 11 | Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS490-TPS490. | 0.8 | 2 |
| 12 | Varlitinib in combination with gemcitabine and cisplatin for treatment-naïve advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 439-439. | 0.8 | 1 |
| 13 | Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 295-295. | 0.8 | 17 |
| 14 | Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. <i>Cancer Research</i> , 2022, 82, P2-13-07-P2-13-07. | 0.4 | 12 |
| 15 | Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 631-643. | 1.9 | 55 |
| 16 | Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naïve patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 522-532. | 3.7 | 149 |
| 17 | Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. <i>European Journal of Cancer</i> , 2022, 169, 188-197. | 1.3 | 3 |
| 18 | Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head&neck cancer. <i>Cancer Medicine</i> , 2022, 11, 2550-2560. | 1.3 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. , 2022, 1, . | | 267 |
| 20 | First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS3153-TPS3153. | 0.8 | 2 |
| 21 | PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an <i>FGFR2</i> gene fusion/rearrangement.. Journal of Clinical Oncology, 2022, 40, TPS4171-TPS4171. | 0.8 | 6 |
| 22 | Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naïve advanced biliary tract cancer.. Journal of Clinical Oncology, 2022, 40, 4117-4117. | 0.8 | 0 |
| 23 | Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).. Journal of Clinical Oncology, 2022, 40, 4075-4075. | 0.8 | 7 |
| 24 | Identifying mechanisms of acquired immune escape from sequential, paired biopsies.. Journal of Clinical Oncology, 2022, 40, 2519-2519. | 0.8 | 0 |
| 25 | Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. Journal of Clinical Oncology, 2022, 40, e14557-e14557. | 0.8 | 0 |
| 26 | Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.. Journal of Clinical Oncology, 2022, 40, TPS4186-TPS4186. | 0.8 | 2 |
| 27 | Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.. Journal of Clinical Oncology, 2022, 40, 4070-4070. | 0.8 | 9 |
| 28 | Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.. Journal of Clinical Oncology, 2022, 40, 4032-4032. | 0.8 | 6 |
| 29 | Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2022, 40, 3929-3939. | 0.8 | 66 |
| 30 | The prognostic role of soluble transforming growth factor- β 2 and its correlation with soluble programmed death-ligand 1 in biliary tract cancer. Liver International, 2021, 41, 388-395. | 1.9 | 4 |
| 31 | Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718. | 3.2 | 27 |
| 32 | Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 1-25. | 1.4 | 29 |
| 33 | Biliary tract cancer. Lancet, The, 2021, 397, 428-444. | 6.3 | 429 |
| 34 | A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. Clinical and Translational Science, 2021, 14, 990-1001. | 1.5 | 0 |
| 35 | Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110428. | 1.4 | 6 |
| 36 | Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients. Cancer Research and Treatment, 2021, 53, 199-206. | 1.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).. Journal of Clinical Oncology, 2021, 39, TPS185-TPS185. | 0.8 | 1 |
| 38 | WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. Gastric Cancer, 2021, 24, 1003-1020. | 2.7 | 16 |
| 39 | A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Investigational New Drugs, 2021, 39, 1324-1334. | 1.2 | 2 |
| 40 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer, 2021, 24, 946-958. | 2.7 | 61 |
| 41 | Safety and activity of the TGF β 2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. , 2021, 9, e002068. | | 95 |
| 42 | Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer. Cancer Research and Treatment, 2021, 53, 471-479. | 1.3 | 2 |
| 43 | Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Research and Treatment, 2021, 53, 291-300. | 1.3 | 8 |
| 44 | Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 7545-7554. | 0.7 | 2 |
| 45 | Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. Journal of Clinical Oncology, 2021, 39, 2565-2565. | 0.8 | 4 |
| 46 | Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut and Liver, 2021, 15, 466-475. | 1.4 | 11 |
| 47 | A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3113-3113. | 0.8 | 3 |
| 48 | Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.. Journal of Clinical Oncology, 2021, 39, e14552-e14552. | 0.8 | 0 |
| 49 | DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.. Journal of Clinical Oncology, 2021, 39, TPS4166-TPS4166. | 0.8 | 2 |
| 50 | Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. Journal of Clinical Oncology, 2021, 39, 4056-4056. | 0.8 | 1 |
| 51 | Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. Journal of Clinical Oncology, 2021, 39, TPS4164-TPS4164. | 0.8 | 1 |
| 52 | The NHance $\text{\textcircled{R}}$ Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. Biomedicines, 2021, 9, 665. | 1.4 | 2 |
| 53 | A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Investigational New Drugs, 2021, 39, 1624-1632. | 1.2 | 0 |
| 54 | Abstract 2073: Co-Targeting PARP and ATR in biliary tract cancer. , 2021, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer. <i>Cancer Letters</i> , 2021, 516, 38-47. | 3.2 | 11 |
| 56 | NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 3.9 | 62 |
| 57 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669. | 3.4 | 194 |
| 58 | Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1468-1482. | 5.1 | 30 |
| 59 | Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy. <i>Scientific Reports</i> , 2021, 11, 296. | 1.6 | 6 |
| 60 | Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS256-TPS256. | 0.8 | 1 |
| 61 | Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 164-164. | 0.8 | 21 |
| 62 | Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 1096-1103. | 1.3 | 9 |
| 63 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153. | 2.7 | 45 |
| 64 | Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 33-39. | 2.8 | 17 |
| 65 | Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020, 71, 422-425. | 2.9 | 32 |
| 66 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519. | 2.7 | 155 |
| 67 | Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194. | 0.8 | 233 |
| 68 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198. | 2.3 | 288 |
| 69 | Ivosidenib in <i>IDH1</i> -mutant, chemotherapy-refractory cholangiocarcinoma (ClariDH): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807. | 5.1 | 620 |
| 70 | Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in patients with pretreated biliary tract cancer. , 2020, 8, e000564. | | 98 |
| 71 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684. | 5.1 | 923 |
| 72 | Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2020, 49, 393-407. | 0.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384. | 1.1 | 62 |
| 74 | Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70. | 3.2 | 27 |
| 75 | Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. <i>Cancer Science</i> , 2020, 111, 513-527. | 1.7 | 32 |
| 76 | Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3063-3063. | 0.8 | 8 |
| 77 | Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3603-3603. | 0.8 | 23 |
| 78 | Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4520-4520. | 0.8 | 63 |
| 79 | Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4597-4597. | 0.8 | 8 |
| 80 | ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3145-TPS3145. | 0.8 | 6 |
| 81 | Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 477-477. | 0.8 | 26 |
| 82 | HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhialuronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 638-638. | 0.8 | 51 |
| 83 | Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-648. | 0.8 | 3 |
| 84 | Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 824-824. | 0.8 | 16 |
| 85 | A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (<i>FGFR2</i>) gene rearrangements (FOENIX-CCA3).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS600-TPS600. | 0.8 | 34 |
| 86 | Comparisons of Clinical Outcomes between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems. <i>Journal of Korean Medical Science</i> , 2020, 35, e117. | 1.1 | 8 |
| 87 | Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 149-166. | 1.3 | 28 |
| 88 | Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 945-956. | 1.3 | 14 |
| 89 | Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1178-1187. | 1.3 | 12 |
| 90 | An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3054-3054. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. Journal of Clinical Oncology, 2020, 38, e16800-e16800. | 0.8 | 0 |
| 92 | Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 4540-4540. | 0.8 | 6 |
| 93 | Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.. Journal of Clinical Oncology, 2020, 38, 686-686. | 0.8 | 0 |
| 94 | Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 712-712. | 0.8 | 5 |
| 95 | Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).. Journal of Clinical Oncology, 2020, 38, 750-750. | 0.8 | 1 |
| 96 | 288â€¦A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. , 2020, , . | | 0 |
| 97 | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Scientific Reports, 2019, 9, 11131. | 1.6 | 21 |
| 98 | Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. JAMA Network Open, 2019, 2, e198243. | 2.8 | 25 |
| 99 | Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage lâ€™III breast cancer patients. British Journal of Cancer, 2019, 121, 230-236. | 2.9 | 14 |
| 100 | Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. British Journal of Cancer, 2019, 121, 332-339. | 2.9 | 19 |
| 101 | Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2019, 5, 1431. | 3.4 | 417 |
| 102 | ATM in DNA repair in cancer. , 2019, 203, 107391. | | 147 |
| 103 | MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Letters, 2019, 465, 12-23. | 3.2 | 21 |
| 104 | Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987112. | 1.4 | 27 |
| 105 | Role of surgical resection in the era of <sc>FOLFIRINOX</sc> for advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 416-425. | 1.4 | 33 |
| 106 | A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. Oncologist, 2019, 24, 1037-e636. | 1.9 | 4 |
| 107 | Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine, 2019, 381, 317-327. | 13.9 | 1,521 |
| 108 | Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. Breast Cancer Research and Treatment, 2019, 176, 453-460. | 1.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Everolimus for the treatment of advanced gastrointestinal or lung neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1717-1728. | 1.0 | 13 |
| 110 | Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 30. | | 68 |
| 111 | GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 932-940. | 2.7 | 12 |
| 112 | Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019, 4, e000575. | 2.0 | 5 |
| 113 | Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients. <i>Biomolecules</i> , 2019, 9, 782. | 1.8 | 7 |
| 114 | APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 4000-4000. | 0.8 | 125 |
| 115 | Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 4034-4034. | 0.8 | 3 |
| 116 | Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. <i>Journal of Clinical Oncology</i> , 2019, 37, 4117-4117. | 0.8 | 63 |
| 117 | A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β 2 receptor kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 4124-4124. | 0.8 | 24 |
| 118 | Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4155-TPS4155. | 0.8 | 20 |
| 119 | Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4-LBA4. | 0.8 | 11 |
| 120 | Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies. <i>Journal of Clinical Oncology</i> , 2019, 37, 331-331. | 0.8 | 9 |
| 121 | Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). <i>Journal of Clinical Oncology</i> , 2019, 37, 387-387. | 0.8 | 90 |
| 122 | MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)-based combinations in gastrointestinal (GI) cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS467-TPS467. | 0.8 | 12 |
| 123 | FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS468-TPS468. | 0.8 | 6 |
| 124 | Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 886-900. | 1.3 | 5 |
| 125 | Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1167-1179. | 1.3 | 22 |
| 126 | Halo 110-101: Early safety results of pegvorhalyuronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC). <i>Journal of Clinical Oncology</i> , 2019, 37, 408-408. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 344-344. | 0.8 | 1 |
| 128 | The prognostic role of soluble transforming growth factor- β 2 (sTGF β 2) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.. <i>Journal of Clinical Oncology</i> , 2019, 37, 257-257. | 0.8 | 0 |
| 129 | Predictive role of temporal changes in intratumoral metabolic heterogeneity during palliative chemotherapy in advanced pancreatic cancer patients: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 311-311. | 0.8 | 0 |
| 130 | A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 319-319. | 0.8 | 1 |
| 131 | Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4059-4059. | 0.8 | 0 |
| 132 | The prognostic role of soluble transforming growth factor- β 2 related with soluble programmed death-ligand 1 in biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4094-4094. | 0.8 | 2 |
| 133 | Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2018, 268, 215-222. | 2.1 | 497 |
| 134 | A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 252. | 1.1 | 7 |
| 135 | Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282. | 0.8 | 524 |
| 136 | Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. <i>Cancer Letters</i> , 2018, 430, 123-132. | 3.2 | 52 |
| 137 | Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4079-4079. | 0.8 | 1 |
| 138 | TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4143-TPS4143. | 0.8 | 3 |
| 139 | A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 217-217. | 0.8 | 28 |
| 140 | The role of soluble TGF-beta and its dynamics for predicting the prognosis in unresectable pancreatic cancer patients treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 288-288. | 0.8 | 1 |
| 141 | Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 470-470. | 0.8 | 16 |
| 142 | MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS530-TPS530. | 0.8 | 6 |
| 143 | HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS543-TPS543. | 0.8 | 1 |
| 144 | Prognostic implication of soluble programmed death-ligand 1 (sPDL1) and its dynamic changes during FOLFIRINOX chemotherapy in unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 306-306. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 164-174. | 2.7 | 13 |
| 146 | Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 254-262. | 2.7 | 51 |
| 147 | Perceived needs for the information communication technology (ICT)-based personalized health management program, and its association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1810-1817. | 1.0 | 9 |
| 148 | Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1145-1154. | 1.9 | 45 |
| 149 | A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1197-1207. | 1.1 | 27 |
| 150 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471. | 6.3 | 1,749 |
| 151 | Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. <i>Cancer Letters</i> , 2017, 411, 162-170. | 3.2 | 10 |
| 152 | Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. <i>Journal of Nuclear Medicine</i> , 2017, 58, 899-904. | 2.8 | 20 |
| 153 | Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. <i>Oncotarget</i> , 2017, 8, 93117-93130. | 0.8 | 28 |
| 154 | Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2017, 49, 851-868. | 1.3 | 50 |
| 155 | Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017, 8, 2329-2341. | 0.8 | 50 |
| 156 | Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5013-5030. | 1.0 | 8 |
| 157 | A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 294-294. | 0.8 | 3 |
| 158 | Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 454-463. | 1.3 | 1 |
| 159 | Prospective evaluation of the clinical implications of the tumor metabolism and chemotherapy-related changes in advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 261-261. | 0.8 | 1 |
| 160 | Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 416-416. | 0.8 | 1 |
| 161 | Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 460-460. | 0.8 | 0 |
| 162 | Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 454-454. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016, 7, 58007-58021. | 0.8 | 63 |
| 164 | Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1515-1524. | 1.9 | 10 |
| 165 | Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515. | 1.1 | 11 |
| 166 | TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205. | 2.9 | 19 |
| 167 | Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2016, 68, 750-755. | 0.9 | 0 |
| 168 | Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. <i>European Radiology</i> , 2016, 26, 2771-2778. | 2.3 | 31 |
| 169 | Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 164-171. | 2.9 | 43 |
| 170 | Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 233-241. | 1.1 | 10 |
| 171 | Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 707-714. | 1.2 | 8 |
| 172 | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 1095-1103. | 2.7 | 33 |
| 173 | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2016, 387, 968-977. | 6.3 | 962 |
| 174 | Pertuzumab in gastrointestinal cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 243-253. | 1.4 | 12 |
| 175 | A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. <i>Supportive Care in Cancer</i> , 2016, 24, 1709-1717. | 1.0 | 19 |
| 176 | Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016, 19, 421-430. | 2.7 | 11 |
| 177 | Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 597-606. | 2.7 | 31 |
| 178 | Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3502-3502. | 0.8 | 114 |
| 179 | Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4009-4009. | 0.8 | 42 |
| 180 | Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4090-4090. | 0.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 517-517. | 0.8 | 2 |
| 182 | A phase 2, open-label, multicenter study of durvalumab (MEDI4736) ± tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4150-TPS4150. | 0.8 | 2 |
| 183 | POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline <i>BRCA1/2</i> mutation (<i>gBRCA<i>m</i>).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4152-TPS4152. | 0.8 | 15 |
| 184 | Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 167-167. | 0.8 | 27 |
| 185 | Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 315-315. | 0.8 | 7 |
| 186 | A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 335-335. | 0.8 | 42 |
| 187 | More Accurate Prediction of Metastatic Pancreatic Cancer Patients's Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. <i>PLoS ONE</i> , 2016, 11, e0145692. | 1.1 | 14 |
| 188 | Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. <i>PLoS ONE</i> , 2016, 11, e0151406. | 1.1 | 15 |
| 189 | Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612. | 0.8 | 93 |
| 190 | Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 28-36. | 1.3 | 20 |
| 191 | The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. <i>Cancer Research and Treatment</i> , 2016, 48, 171-179. | 1.3 | 56 |
| 192 | Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1045-1055. | 1.3 | 10 |
| 193 | Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. <i>Cancer Research and Treatment</i> , 2016, 48, 990-997. | 1.3 | 15 |
| 194 | Role of adjuvant chemoradiotherapy for duodenal cancer: An update of the experience at a single institution.. <i>Journal of Clinical Oncology</i> , 2016, 34, 370-370. | 0.8 | 0 |
| 195 | TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4075-4075. | 0.8 | 0 |
| 196 | Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23268-e23268. | 0.8 | 0 |
| 197 | A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2521-2521. | 0.8 | 1 |
| 198 | Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. <i>Clinical Epigenetics</i> , 2015, 7, 63. | 1.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. <i>BMC Cancer</i> , 2015, 15, 690. | 1.1 | 9 |
| 200 | Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. <i>BMC Cancer</i> , 2015, 15, 721. | 1.1 | 19 |
| 201 | Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015, 17, 33. | 2.2 | 138 |
| 202 | Treatment for unresectable gastric cancer. <i>Journal of the Korean Medical Association</i> , 2015, 58, 209. | 0.1 | 1 |
| 203 | Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. <i>PLoS ONE</i> , 2015, 10, e0139749. | 1.1 | 183 |
| 204 | Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2015, 47, 343-361. | 1.3 | 75 |
| 205 | Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. <i>Oncologist</i> , 2015, 20, 926-933. | 1.9 | 15 |
| 206 | Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2520-2529. | 3.2 | 59 |
| 207 | Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4050-4050. | 0.8 | 1 |
| 208 | Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAB), in patients (pts) with HER2-positive advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 523-523. | 0.8 | 3 |
| 209 | Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2015, 33, 276-276. | 0.8 | 2 |
| 210 | Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 687-696. | 1.3 | 11 |
| 211 | Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015, 47, 607-615. | 1.3 | 93 |
| 212 | Adjuvant treatment patterns and clinical outcomes in patients with curative resected ampulla of Vater cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 415-415. | 0.8 | 1 |
| 213 | Change of skeletal muscle index during the chemotherapy as a prognostic factor of survival in pancreatic cancer patients receiving palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 363-363. | 0.8 | 0 |
| 214 | Weight loss at the first month of palliative chemotherapy to predict survival outcomes in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 83-83. | 0.8 | 0 |
| 215 | Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15197-e15197. | 0.8 | 0 |
| 216 | Measurement of soluble Programmed Death-Ligand 1 (soluble PD-L1) to predict survival in biliary tract cancer patients treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11094-11094. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. American Journal of Cancer Research, 2015, 5, 3376-88. | 1.4 | 6 |
| 218 | Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. Journal of Korean Medical Science, 2014, 29, 1094. | 1.1 | 22 |
| 219 | The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. Journal of Pain and Symptom Management, 2014, 48, 13-25. | 0.6 | 17 |
| 220 | A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 2014, 50, 2072-2081. | 1.3 | 283 |
| 221 | ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2014, 32, 1038-1038. | 0.8 | 0 |
| 222 | Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Research, 2014, 34, 4275-80. | 0.5 | 7 |
| 223 | Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2013, 45, 325-333. | 1.3 | 49 |
| 224 | Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer, 2012, 118, 6162-6170. | 2.0 | 83 |
| 225 | A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational New Drugs, 2012, 30, 1164-1174. | 1.2 | 19 |
| 226 | Evaluation of the willingness to pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross-sectional study. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 282-291. | 0.7 | 18 |
| 227 | Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. Journal of Neuro-Oncology, 2012, 106, 303-313. | 1.4 | 64 |
| 228 | A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3076-3076. | 0.8 | 6 |
| 229 | Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1. | 0.8 | 29 |
| 230 | Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1. | 0.8 | 34 |
| 231 | Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. Journal of Clinical Oncology, 2012, 30, 98-98. | 0.8 | 2 |
| 232 | Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2012, 30, 269-269. | 0.8 | 2 |
| 233 | Genetic polymorphisms and ethnic difference in outcome of adjuvant FOLFOX chemotherapy in Korean patients with colon cancer.. Journal of Clinical Oncology, 2012, 30, 623-623. | 0.8 | 0 |
| 234 | Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 3624-3624. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, e14617-e14617. | 0.8 | 0 |
| 236 | Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization. Diagnostic Molecular Pathology, 2011, 20, 94-100. | 2.1 | 31 |
| 237 | Public Awareness of Gastric Cancer Risk Factors and Disease Screening in a High Risk Region: A Population-Based Study. Cancer Research and Treatment, 2009, 41, 59. | 1.3 | 34 |
| 238 | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer, 2009, 65, 80-84. | 0.9 | 118 |
| 239 | The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Letters, 2008, 272, 296-306. | 3.2 | 111 |
| 240 | TGF- β 2 Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. Cancer Research and Treatment, 1970, 47, 101-109. | 1.3 | 13 |
| 241 | A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene, 0, , . | 2.6 | 3 |